文献速递白血病淋巴瘤

从单细胞到PAX5驱动白血病轨迹揭示体内PAX5-MYC相互作用

Trajectories from single-cells to PAX5-driven leukemia reveal PAX5-MYC interplay in vivo.
PubMed 文献 · Leukemia · 2025-05-20

研究在单细胞水平纵向分析PAX5降低对健康、白血病前及BCP-ALL细胞的影响,发现Pax5±小鼠pre-BII细胞富集且B细胞受体信号下调,Pax5±白血病前细胞丧失B细胞身份并激活Myc,随后BCP-ALL获得RAG介导的异常及JAK-STAT和RAS通路驱动突变,表明PAX5降低通过激活MYC足以启动向BCP-ALL的克隆演化。

要点

  • Pax5±小鼠pre-BII细胞富集,B细胞受体信号下调而DNA复制/修复和细胞周期通路上调。
  • Pax5±白血病前细胞丧失B细胞身份并显示Myc激活。
  • PAX5降低通过激活MYC足以启动向BCP-ALL的克隆演化。

核心结论

  • PAX5降低通过激活MYC足以启动向BCP-ALL的克隆演化,并揭示PAX5介导的白血病前细胞进展中的分子和功能检查点。

研究设计与样本

  • 研究对健康、白血病前和BCP-ALL细胞进行单细胞水平纵向分析,包括Pax5±小鼠细胞表面标志分析、移植实验、单细胞RNA测序和bulk ATAC测序。

主要发现

  • Pax5±小鼠中pre-BII群体富集,该群体B细胞受体信号下调而DNA复制/修复和细胞周期信号通路上调。
  • 观察到kappa/lambda轻链比值向lambda重排B细胞偏移。
  • 移植实验验证Pax5± pre-BII细胞成熟和向IgM阳性转变延迟。
  • Pax5±白血病前细胞丧失B细胞身份并显示Myc激活,随后BCP-ALL获得RAG介导的额外异常及JAK-STAT和RAS信号通路驱动突变。

临床怎么用

  • 作者认为PAX5介导的白血病前细胞进展中的分子和功能检查点可用于治疗干预。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PAX5 acts as a master regulator of B-cell proliferation and differentiation. Its germline and somatic deregulation have both been implicated in the development of B-cell precursor acute lymphoblastic leukemia (BCP-ALL). However, the process how reduced PAX5 transcriptional activity mediates progression to BCP-ALL, is still poorly understood. Here, we characterized the longitudinal effects of PAX5 reduction on healthy, pre-leukemic and BCP-ALL cells at the single-cell level. Cell-surface marker analysis revealed a genotype-driven enrichment of the pre-BII population in healthy Pax5± mice. This population showed downregulated B-cell receptor signaling, while DNA replication/repair and cell-cycle signaling pathways were upregulated. Moreover, we observed a shift in the kappa/lambda light chain ratio toward lambda rearranged B-cells. Transplantation experiments further validated a delay of Pax5± pre-BII cells in maturation and transition to IgM-positivity. Additionally, single-cell RNA-Sequencing and bulk ATAC-Sequencing of different stages of BCP-ALL evolution showed that Pax5± pre-leukemic cells lose their B-cell identity and display Myc activation. Subsequently, BCP-ALLs acquired additional RAG-mediated aberrations and driver mutations in JAK-STAT and RAS-signaling pathways. Together, this study elucidates molecular and functional checkpoints in PAX5-mediated pre-leukemic cell progression exploitable for therapeutic intervention and demonstrates that PAX5 reduction is sufficient to initiate clonal evolution to BCP-ALL through activation of MYC.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Auer F, Morcos MNF, Sipola M, et al. Trajectories from single-cells to PAX5-driven leukemia reveal PAX5-MYC interplay in vivo. Leukemia. 2025. PMID: 40394211. doi:10.1038/s41375-025-02626-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。